Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02027064|
Recruitment Status : Unknown
Verified September 2016 by Xiaojun Huang, Peking University People's Hospital.
Recruitment status was: Recruiting
First Posted : January 3, 2014
Last Update Posted : September 29, 2016
molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.
Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.
the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Drug: Interferon-alpha||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||October 2017|
|Estimated Study Completion Date :||October 2017|
- relapse rate [ Time Frame: participants will be followed for an expected average of 365 days ]number of participants with morphologic relapse at one year
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02027064
|Contact: yu wang, M.D.||861088326666 ext firstname.lastname@example.org|
|Peking University People's Hospital||Recruiting|
|Beijing, China, 100044|
|Contact: yu wang, M.D. 861088326666 ext 4952 email@example.com|
|Principal Investigator: xiao-jun huang, M.D.|